MZT2B and neoplasm: Quantitative assessment of immunoblots across the entire patient cohort (n = 20) further corroborated a significant elevation of MZT2B protein abundance in NSCLC tumor tissues relative to the adjacent non-malignant controls (Fig. 4C).